8-K: Hawkins Reports Record Q3 Revenue, EBITDA Amid Acquisitions

Hawkins, Inc. announced record third-quarter revenue, gross profit, operating income, and adjusted EBITDA, driven by strategic acquisitions and segment growth, despite a slight dip in diluted EPS.

Summary

• Hawkins, Inc. achieved record third-quarter fiscal 2026 results in revenue, gross profit, operating income, and adjusted EBITDA.
• Total revenue grew 8% to $244.1 million compared to the prior year's third quarter.
• Water Treatment segment sales increased 21% to $120.5 million, including $19 million from acquisitions.
• Industrial Solutions segment sales increased 10% to $53.6 million.
• Diluted earnings per share (EPS) decreased 4% to $0.69, primarily due to a $5 million increase in amortization and interest expense from six acquisitions, including WaterSurplus.
• Pro forma EPS, assuming WaterSurplus was acquired at the beginning of the prior fiscal year, would have been approximately 10% higher.
• Adjusted EBITDA rose 3% to $34.8 million, with trailing 12-month Adjusted EBITDA reaching $179 million.
• Operating cash flow for the quarter was $35 million, used in part to pay down $15 million of debt, reducing the leverage ratio to 1.47x Adjusted EBITDA.
• The company completed its sixth acquisition of fiscal 2026, Redbird Chemical, in December.

Sentiment

Score: 7

Explanation: The company reported record top-line and operational profit metrics, demonstrating strong growth driven by strategic acquisitions. While diluted EPS saw a slight decline due to acquisition-related expenses, the pro forma EPS showed healthy growth, and management expects the largest acquisition to become accretive soon. The significant cash generation and debt reduction are positive. However, the decline in the Food & Health Sciences segment and anticipated pricing pressures introduce some caution.

Positives

• Record third-quarter results for revenue ($244.1 million), gross profit ($50.8 million), operating income ($22.6 million), and adjusted EBITDA ($34.8 million).
• Overall revenue growth of 8% year-over-year.
• Strong segment growth in Water Treatment (21% increase to $120.5 million) and Industrial Solutions (10% increase to $53.6 million).
• Pro forma EPS, accounting for the WaterSurplus acquisition, would have been approximately 10% higher than the prior year.
• Generated significant operating cash flow of $35 million in the quarter.
• Successfully paid down $15 million of debt, lowering the leverage ratio to 1.47x Adjusted EBITDA.
• WaterSurplus acquisition revenue base is growing between 15% to 20% in calendar year 2025, meeting expectations.
• Strategic investments are aimed at delivering 15% or more revenue growth and 20% or better Adjusted EBITDA margins.

Negatives

• Diluted earnings per share (EPS) decreased by $0.03, or 4%, to $0.69, primarily due to a $5 million increase in amortization and interest expense related to recent acquisitions.
• Net income decreased to $14.3 million from $15.0 million in the prior year's third quarter.
• Food & Health Sciences segment sales decreased 10% to $70.0 million due to decreased sales volumes.
• Gross profit margin for the Water Treatment segment slightly decreased from 26% to 25% of sales.
• Gross profit margin for the Food & Health Sciences segment decreased from 21% to 20% of sales.
• The WaterSurplus acquisition continues to impact operating income and EPS by $4 to $5 million per quarter due to associated expenses, with one quarter of this impact remaining.
• Anticipated continued pricing pressures within food end markets in the fourth quarter.
• Leverage ratio increased to 1.47x trailing 12-month adjusted EBITDA from 0.86x at the end of fiscal 2025, primarily due to acquisition financing.

Risks

• Changes in competition and price pressures.
• Changes in demand and customer requirements or processes for products.
• Availability of product and disruptions to supplies.
• Interruptions in production resulting from hazards, transportation limitations, or other extraordinary events outside the company's control.
• Changes in imported products and tariff levels.
• The availability of products and the prices at which they are available.
• The acceptance of new products by customers and the timing of any such acceptance.
• Changes in product supplies.

Future Outlook

Management expects continued pricing pressures in food end markets for the fourth quarter of fiscal 2026, with a focus on returning the Food and Health Sciences segment to growth. The WaterSurplus acquisition is anticipated to become accretive in fiscal 2027, and the company expects to return to historical organic revenue growth rates in fiscal 2027. The strategic focus remains on investing in higher-margin businesses, pursuing accretive acquisitions, and maintaining high levels of customer service.

Management Comments

• "Our third quarter performance was highlighted by another quarter of record results in revenue, gross profit, operating income and Adjusted EBITDA."
• "The key drivers were our ongoing acquisition activity within the Water Treatment segment and the continued improvement in our Industrial Solutions segment."
• "From a bottom-line perspective, proforma EPS grew 10% in the quarter over the prior year and Adjusted EBITDA continued to grow."
• "Once again, our performance generated significant cash that we used to pay down debt, fund investments in the business, and close acquisitions as part of our growth strategy for our largest segment, Water Treatment."
• "As previously communicated, we are experiencing a continued impact on operating income and earnings per share from the first-quarter acquisition of WaterSurplus, due to $4 to $5 million per quarter of expense related to the acquisition associated with amortization, earn-out accretion and interest expense with one quarter of this impact remaining before we lap it."
• "We expect this acquisition to be accretive in fiscal 2027 with our continued growth of the business."
• "We continue to be pleased with the integration of WaterSurplus to date, including growing the revenue base between 15 to 20% as expected in calendar year 2025."
• "Overall, we have been making investments in the business to ensure that it continues to deliver revenue growth of 15% or more and Adjusted EBITDA margins of 20% or better."
• "Looking to the fourth quarter, we will continue to see pricing pressures within food end markets and are focused on returning our Food and Health Sciences segment to growth."
• "We also believe we will start to return to historical organic revenue growth rates in fiscal 2027 and will continue to deliver on our strategy of investing in our higher margin businesses, acquiring companies that are accretive, and servicing the needs of our customers to the highest level possible."

Industry Context

Hawkins, Inc.'s performance reflects a strategic focus on consolidation and expansion within the specialty chemicals and water treatment sectors, a trend observed across the industry as companies seek to gain market share and operational efficiencies through M&A. The strong growth in the Water Treatment segment, fueled by acquisitions, aligns with increasing global demand for water purification and management solutions. The challenges in the Food & Health Sciences segment, particularly pricing pressures, indicate a more competitive or volatile environment in certain end markets, contrasting with the robust performance in industrial solutions. The company's emphasis on higher-margin businesses and accretive acquisitions is a common strategy to enhance shareholder value in mature industrial sectors.

Comparison to Industry Standards

• The company's strategy of acquiring companies that are accretive and investing in higher-margin businesses is a standard practice for growth-oriented chemical distributors and specialty ingredient companies.
• The reported revenue growth of 8% and Adjusted EBITDA growth of 3% should be benchmarked against peers in the specialty chemicals and water treatment industries, such as Ecolab, Nalco Water, or other regional distributors, to assess relative performance.
• The leverage ratio of 1.47x Adjusted EBITDA, while higher than the previous fiscal year-end, remains within a manageable range for a company actively pursuing acquisitions, though it warrants monitoring compared to industry averages for similar growth strategies.
• The 15-20% revenue growth for the WaterSurplus acquisition in calendar year 2025 is a strong indicator of successful integration and market penetration, potentially outperforming organic growth rates of some industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from record revenue and EBITDA, strategic growth through acquisitions, and debt reduction. However, the temporary dip in GAAP EPS due to acquisition costs might be a short-term concern, offset by pro forma growth and future accretion expectations.
• Employees: Continued growth and acquisition activity suggest stability and potential opportunities, particularly in the Water Treatment segment.
• Customers: Enhanced product offerings and service capabilities through acquisitions like Redbird Chemical and WaterSurplus.
• Creditors: Debt reduction and a manageable leverage ratio (1.47x Adjusted EBITDA) indicate sound financial management, though total debt increased due to acquisitions.

Next Steps

• Focus on returning the Food and Health Sciences segment to growth.
• Continue to manage pricing pressures within food end markets.
• Continue to deliver on the strategy of investing in higher margin businesses.
• Continue to acquire companies that are accretive.
• Continue servicing the needs of customers to the highest level possible.
• Expect WaterSurplus acquisition to be accretive in fiscal 2027.
• Expect a return to historical organic revenue growth rates in fiscal 2027.

Key Dates

Recommendation

While Hawkins, Inc. delivered record top-line and operational profit figures, demonstrating effective execution of its acquisition-led growth strategy, the slight decline in GAAP EPS due to integration costs warrants a cautious approach. The pro forma EPS growth and expected accretion of WaterSurplus in fiscal 2027 are positive indicators for future performance. However, the challenges in the Food & Health Sciences segment and anticipated pricing pressures suggest some headwinds. The company's strong cash flow and debt management are commendable. Given the mixed signals—strong growth offset by a temporary EPS dip and segment-specific challenges—a "hold" recommendation is appropriate, allowing investors to monitor the successful integration of acquisitions and the turnaround in the Food & Health Sciences segment before making further commitments.

Keywords

Hawkins Inc., HWKN, Q3 2026 Earnings, Financial Results, Water Treatment, Industrial Solutions, Food & Health Sciences, Acquisitions, Adjusted EBITDA, EPS, Revenue Growth, Specialty Chemicals, Chemical Distribution, Corporate Governance, SEC Filing